Emmaus Life Sciences is a predictive analytics company. Co. employs a platform to support personalized care for mental health patients. Co. utilizes its machine learning, artificial intelligence, data analytics platform for the delivery of telebehavioral health services and its Psychiatric Electroencephalograms (EEGs) Evaluation Registry (PEER) predictive analytics product offering. Co.'s platform (PEER Online) utilizes algorithms to analyze EEGs to generate PEER Reports to predict individual responses to a range of medications prescribed for the treatment of behavioral disorders including depression, anxiety, bipolar disorder, post-traumatic stress disorder and other non-psychotic disorders. The EMMA stock yearly return is shown above.
The yearly return on the EMMA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EMMA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|